A5083261388- Antifungal resistance and susceptibility
- Fungal Infections and Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Mycobacterium research and diagnosis
- Tuberculosis Research and Epidemiology
- Transplantation: Methods and Outcomes
- Herpesvirus Infections and Treatments
- COVID-19 Clinical Research Studies
- Cytomegalovirus and herpesvirus research
- Long-Term Effects of COVID-19
- Infectious Diseases and Mycology
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Bacterial Infections and Vaccines
- Respiratory viral infections research
- Plant Pathogens and Fungal Diseases
- Virology and Viral Diseases
- SARS-CoV-2 and COVID-19 Research
- Antimicrobial Resistance in Staphylococcus
- Infectious Aortic and Vascular Conditions
- Organ Transplantation Techniques and Outcomes
- Streptococcal Infections and Treatments
- Infections and bacterial resistance
- Immunodeficiency and Autoimmune Disorders
- Toxoplasma gondii Research Studies
Mayo Clinic in Florida
2016-2025
Jacksonville College
2007-2025
WinnMed
2008-2024
Mayo Clinic
2006-2022
Robert Bosch (United States)
2021
WiLAN (Canada)
2021
Mayo Clinic in Arizona
2016-2020
Office of Infectious Diseases
2012
Nemours Children's Clinic
2011
University of Alabama at Birmingham
2010
Invasive fungal infections (IFIs) are a major cause of morbidity and mortality among organ transplant recipients. Multicenter prospective surveillance data to determine disease burden secular trends lacking.The Transplant-Associated Infection Surveillance Network (TRANSNET) is consortium 23 US centers, including 15 that contributed the recipient dataset. We prospectively identified IFIs recipients from March, 2001 through 2006 at these sites. To explore trends, we calculated 12-month...
The incidence and epidemiology of invasive fungal infections (IFIs), a leading cause death among hematopoeitic stem cell transplant (HSCT) recipients, are derived mainly from single-institution retrospective studies.The Transplant Associated Infections Surveillance Network, network 23 US centers, prospectively enrolled HSCT recipients with proven probable IFIs occurring between March 2001 2006. We collected denominator data on all HSCTs preformed at each site clinical, diagnostic, outcome...
Abstract Recent reports describe increasing incidence of non-Aspergillus mold infections in hematopoietic cell transplant (HCT) and solid organ (SOT) recipients. To investigate the epidemiology with Mucorales, Fusarium spp., Scedosporium spp. molds, we analyzed data from Transplant-Associated Infection Surveillance Network, 23 centers that conducted prospective surveillance for invasive fungal during 2001–2006. We identified 169 (105 37 27 spp.) patients; 124 (73.4%) were HCT recipients, 45...
Abstract Background Invasive candidiasis ( IC ) is a common cause of mortality in solid organ transplant recipients OTR s), but knowledge epidemiology this population limited. Method The present analysis describes data from 15 US centers that prospectively identified nearly 17 000 s. Analyses were undertaken to determine predictors infection and mortality. Results A total 639 cases identified. most species was Candida albicans (46.3%), followed by glabrata (24.4%) parapsilosis (8.1%). In 68...
Abstract Background Bamlanivimab and casirivimab-imdevimab are authorized for emergency use treatment of mild to moderate coronavirus disease 2019 (COVID-19) in patients at high risk developing severe or hospitalization. Their safety efficacy have not been specifically evaluated solid organ transplant recipients. Methods We retrospectively reviewed recipients who received monoclonal antibody infusion COVID-19 Mayo Clinic sites through January 23, 2021. Outcomes included department visit,...
Solid organ transplant recipients (SOTRs) are at high-risk for severe infection from acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Anti-spike monoclonal antibodies currently utilized under emergency use authorization to prevent hospitalization in individuals with disease 2019 (COVID-19), including SOTRs. However, clinical data bebtelovimab, the sole available anti-spike antibody COVID-19, is limited.We conducted a retrospective cohort study of adult SOTRs diagnosed mild-to-moderate...
The frequency and complications of respiratory viral infections (RVI) were studied in 50 ambulatory lung transplant patients during a single winter season, using antigens, cultures PCR nasal washes or bronchoalveolar lavages. Patients' survival, episodes acute rejection occurrence bronchiolitis obliterans (BO) BO syndrome (BOS) monitored for 1 yr after the study. Overall, 32 (64%) had 49 symptomatic episodes. Documented included eight due to syncytial virus (RSV), one parainfluenza (PIV) 10...
As invasive mucormycosis (IM) numbers rise, clinicians suspect prior voriconazole worsens IM incidence and severity, believe combination anti-fungal therapy improves survival. To compare the cumulative (CI), severity mortality of in eras immediately before after commercial availability all cases from 1995 to 2011 were analysed across four risk-groups (hematologic/oncologic malignancy (H/O), stem cell transplantation (SCT), solid organ (SOT) other), two eras, E1 (1995-2003) E2, (2004-2011)....
ABSTRACT Introduction Vaccination is crucial to the thoracic solid organ transplant (SOT) population reduce vaccine‐preventable infection. However, data on posttransplant hepatitis B virus (HBV) vaccination compliance and vaccine‐induced seroprotection are lacking. Methods We conducted a retrospective study of adult (heart lung) recipients at Mayo Clinic sites in Minnesota, Arizona, Florida between January 2018 August 2023. Recombivax HB was used before 2020, Heplisav‐B preferred after 2020....
ABSTRACT Invasive fungal infections (IFI) are a major cause of morbidity and mortality among both solid organ transplant (SOT) hematopoietic stem cell (HSCT) recipients. Candida is the most common IFI in SOT recipients second HSCT We determined susceptibilities to fluconazole, voriconazole, itraconazole, posaconazole, amphotericin B, caspofungin for 383 invasive sp. isolates from enrolled Transplant-Associated Infection Surveillance Network correlated these results clinical data. Fluconazole...
ABSTRACT Introduction Hepatitis B virus reactivation (HBVr) can occur in solid organ transplant (SOT) recipients with previously inactive hepatitis (HBV) infection. Previous studies have reported that HBVr is generally less than 10% nonliver SOT past HBV Methods We conducted a retrospective study from January 2018 to August 2023 at Mayo Clinic sites Arizona, Florida, and Minnesota. examined the antiviral prophylaxis strategy used characteristics of core antibody‐positive (HBcAb +) adult...
Antifungal prophylaxis has been proposed for liver transplant recipients at increased risk invasive mold infection. Risk factors infection after transplantation were selected to divide into 3 groups: (1) high risk—transplantation on hemodialysis or delay of hospital discharge beyond day 7 because allograft renal insufficiency; (2) intermediate risk—retransplantation fulminant hepatic failure; (3) low risk—absence conditions in groups 1 and 2. During an intervention period (February...
Bordetella bronchiseptica is an uncommon cause of respiratory infection in humans generally occurring immunocompromised individuals exposed to infected animals. A 61-year-old female underwent a kidney-pancreas transplant 7 years before presentation. Postoperative immunosuppression was achieved with sirolimus and mycophenolate mofetil. The patient doing well until she developed small bowel obstruction secondary adhesions. She surgical adhesiolysis without complications. Two weeks...
Here we describe the first reported case of Nocardia beijingensis infection in United States, made rarer by its presence an immunocompetent patient.
ABSTRACT Introduction Hepatitis B virus (HBV) vaccination is recommended for solid organ transplant (SOT) candidates. However, there a lack of data on the HBV vaccine compliance, serologic response, and durability seroprotection in thoracic transplantation recipients. Methods We conducted retrospective study adult (heart lung) candidates who received at Mayo Clinic sites Minnesota, Arizona, Florida between January 2018 August 2023. Conventional recombinant hepatitis (Recombivax HB) was used...
Background Pneumocystis jirovecii pneumonia (PJP) is a potentially fatal infection afflicting the immunocompromised population, including solid organ transplant (SOT) recipients. Several risk factors have been described; however, little known regarding of PJP in SOT recipients with posttransplant lymphoproliferative disorder (PTLD). Methods We performed nested case-control study diagnosed from 2000 to 2020. was defined as positive microscopy or polymerase chain reaction testing compatible...
Antispike monoclonal antibody treatment of 180 B-cell-depleted patients with mild-to-moderate coronavirus disease 2019 (COVID-19) resulted in good outcomes overall, only 12.2% progressing to severe disease, 9.4% requiring hospitalization, 0.6% mechanical ventilation, no deaths within 30 days, and 1.8% developing persistent COVID-19. antibodies appear effective this immunocompromised population.
Tumor necrosis factor-a inhibitors can be associated with increased risk of infections, particularly reactivation latent tuberculosis or nontuberculous mycobacterium (NTM). However, because disseminated NTM is rare, inborn errors immunity should considered. We present three patients after tumor inhibitor use who were found to have immunity.
Background. Solid organ transplant (SOT) candidates should be screened and treated for latent tuberculosis infection (LTBI) to prevent (TB) reactivation after transplantation. We aimed assess the steps from positive QuantiFERON (QFT) through LTBI treatment (cascade of care) in SOT population. Methods. conducted a retrospective study recipients older than 18 y with QFT during pretransplant evaluation at Mayo Clinic January 2010 June 2023. analyzed each cascade step determine associated...